Tag: immunotherapies
MaaT Pharma presents promising preclinical data at AACR for MaaT034 aimed at improving patient responses to immunotherapies – 04/08/2024 at 7:30 p.m.
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aimed to Improve Patient Responses to Immunotherapies Lyon, France, April 8, 2024, 7:20 p.m. CET – MaaT Pharma (EURONEXT: MAAT…
MaaT Pharma announces the initiation of an investigator-sponsored Phase 2a clinical trial evaluating MaaT013 in combination with immunotherapies for patients with melanoma – 04/07/2022 at 18:10
MaaT Pharma (EURONEXT: MAAT – the “Company”), a French late-stage biotechnology company, a pioneer in the development of drugs to restore the gut microbiota to improve the survival of cancer…
Nanobiotix announces the publication of new preclinical data describing the potential of combining NBTXR3 with anti-PD-1 and anti-CTLA-4 immunotherapies – 01/26/2022 at 22:29
Data published in the International Journal of Nanobiotechnology – New preclinical data (published in a peer-reviewed journal) from a model of anti-PD-1 resistant lung cancer shows that adding NBTXR3 to…